Allied Market Research
Loading...
Cart
0
New
New Allied Market Research

LATAM women Hypoactive Sexual Desire Disorder (HSDD) Treatment Market by Treatment Type (Buspirone, Bupropion, Bremelanotide, and Flibanserin), Sales Channel (Hospitals, Clinics, and Online Retailers): Regional Opportunity Analysis and Industry Forecast, 2020–2027

A07587
Pages: 150
Oct 2020 | 254 Views
 
Author(s) : Sanjivan Gill , Onkar Sumant
Tables: 71
Charts: 31
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Latam Women Hypoactive Sexual Desire Disorder (hsdd) Treatment Market

Request Now !

LATAM Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Overview:

The LATAM women hypoactive sexual desire disorder treatment market accounted for $967 million in 2019, and is expected to reach $1,275 million by 2027, registering a CAGR of 6.1% from 2020 to 2027.

Bremelanotide and Flibanserin segment is expected to witness a decline. As these products are prescription based, hence the low availabilty of healthcare physicians to address non-COVID-19 healthcare issues in the region lead to the negative impact.

Hyposexual desire disorder (HSDD) in women is defined as deficiency or lack of sexual fantasies and desire of sexual activity. Furthermore, HSDD is a highly prevalent sexual desire disorder in women, which can severely impact the quality of life of a patient. Thus, treatment is required, which involves use of certain drugs such as bupropion, buspirone, bremelanotide, and flibanserin. These drugs have varying mechanism of action on HSDD. For instance, the FDA approved treatment bremelanotide works by lowering serotonin levels in brain and increasing norepinephrine and dopamine neurotransmitters. Furthermore, women hypoactive sexual desire disorder treatments are available in hospitals, clinics, and through online retailers.

LATAM-Women-Hypoactive-Sexual-Desire-Disorder-Treatment-Market,-2020-2027

Get more information on this report : Request Sample Pages

The factors that contribute to LATAM women hypoactive sexual desire disorder treatment market growth include rise in prevalence of lifestyle ailments, such as stress, depression, anxiety, and prolonged fatigue, and rise in use of medicines, which induces state of hypoactive sexual desire disorder. For instance, stress can lead to release of hormones such as cortisol and epinephrine. These hormones in high levels can lead to diminished sex drive. Similarly, depression is marked by depressed mood, decreased energy, and loss of interest in pleasurable activities. In addition, rise in number of surgical procedures, which lead to sexual dysfunction, are expected to boost LATAM women hypoactive sexual desire disorder treatment market growth during the forecast period. However, lack in awareness related to hypoactive sexual desire disorder are anticipated to hamper the market growth during the forecast period. For instance, there is a lack of public education on sexual health issues in many countries of Latin America such as Brazil and Guyana. This contributes to low diagnosis of HSDD in these countries. Moreover, presence of strong pipeline products, which are in their late phases of clinical trials are expected to get approved for commercialization in coming years. Hence, presence of pipeline drugs offer a lucrative opportunity for the LATAM women hypoactive sexual desire disorder treatment market.

COVID-19 Impact Analysis on LATAM women hypoactive sexual desire disorder treatment market

COVID-19 pandemic has affected every business adversely. For instance, after COVID-19 was declared as a pandemic by the WHO, countries worldwide adopted nationwide lockdowns to observe social distancing as a measure to contain the spread. This led to disruption, limitation, challenges, and changes in each sector of every industry in Latin America. Similarly, COVID-19 impacted off label generic HSDD treatments in a negative manner. This was attributed to the fact that initial breakout of the virus led to strict lockdowns throughout the world, which, in turn, led to a decline in logistic services Furthermore, the healthcare system during the pandemic became more focused on providing care to COVID-19 patients. This led to rescheduling of doctor appointments, which were of elective nature. Thus, demand for HSDD drugs during the initial period of pandemic is estimated to have suffered a decline. However, as the situation around pandemic is gradually becoming better, the supply is expected to be restored. 

Latam Women Hypoactive Sexual Desire Disorder Treatment Market Segmentation  

The LATAM women hypoactive sexual desire disorder treatment market is segmented on the basis of treatment type, sales channel, and country. By treatment type, the market is categorized into buspirone, bupropion, bremelanotide, and flibanserin. On the basis of sales channel, it is divided into hospitals, clinics, and online retailers. Country wise, the LATAM women hypoactive sexual desire disorder treatment market size is studied across Brazil, Argentina, Chile, Colombia, and rest of the LATAM.

Segment Review

By type, the LATAM hypoactive sexual desire disorder treatment market is segmented into buspirone, bupropion, bremelanotide, and flibanserin. The bremelanotide segment is expected to exhibit fastest growth rate during the forecast period, owing to the fact that it is FDA approved treatment aimed at HSDD in premenopausal women, which makes it a preferred brand over the off label treatments. Furthermore, this treatment type has lesser side effects as compared to other treatment options present in the market.

LATAM women Hypoactive Sexual Desire Disorder (HSDD) Treatment Market
By Treatment Type

Your browser does not support the canvas element.

Bremelanotide segment is projected as one of the most lucrative segment.

Get more information on this report : Request Sample Pages

By sales channel, the hospitals segment occupied the major LATAM women hypoactive sexual desire disorder treatment market share in 2019, owing to the fact that the treatment of HSDD requires specialist availability in hospitals. In addition, the clinics segment is expected to witness highest growth rate during the forecast period, owing to rise in awareness related to diagnosis and treatment of HSDD, which is expected to contribute toward surge in number of clinics providing such services.    

LATAM women Hypoactive Sexual Desire Disorder (HSDD) Treatment Market
By Sales Channel

Your browser does not support the canvas element.

Hospitals segment held a dominant position in 2019 and will continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

Country wise, Argentina is expected to exhibit the fastest growth during the forecast period. This is attributed to factors such as rise in healthcare infrastructure, surge in healthcare expenditure, and rise in awareness related to hypoactive sexual desire disorder. In addition, Brazil acquired the major share of LATAM women hypoactive sexual desire disorder treatment market size, owing to the presence of large patient base.

LATAM women Hypoactive Sexual Desire Disorder (HSDD) Treatment Market
By Country

2027
Brazil 
Argentina
Chile
Colombia
Rest Of Latam

Argentina would exhibit the highest CAGR of 7.7% during 2020-2027.

Get more information on this report : Request Sample Pages

The LATAM women hypoactive sexual desire disorder treatment market is highly competitive and prominent players in the market have adopted various strategies to garner maximum LATAM women hypoactive sexual desire disorder treatment market share. These include collaboration, product launch, partnership, and acquisition. Major players operating in the market include Aurobindo Pharma, Bristol-Myers Squibb Company, GlaxoSmithKline Plc, Mylan N.V., Novartis AG, Palatin Technologies, Inc., Sprout Pharmaceuticals, Inc., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., and Zydus Cadila.

Key Benefits For Stakeholders

  • This report entails a detailed quantitative analysis along with the current LATAM women hypoactive sexual desire disorder treatment market trends from 2019 to 2027 to identify the prevailing opportunities along with the strategic assessment.
  • The LATAM women hypoactive sexual desire disorder treatment market forecast is studied from 2020 to 2027. 
  • The market size and estimations are based on a comprehensive analysis of key developments in the industry. 
  • A qualitative analysis based on innovative products facilitates strategic business planning.
  • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the LATAM women hypoactive sexual desire disorder treatment market.

Key Market Segments

By Treatment Type

  • Buspirone
  • Bupropion
  • Bremelanotide
  • Flibanserin

By Sales Channel

  • Hospitals
  • Clinics
  • Online Retailers

By Country

  • Brazil
  • Argentina
  • Chile
  • Colombia
  • Rest of LATAM
 

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools & models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key Findings

3.2.1.Top Winning Strategies
3.2.2.Top investment pockets

3.3.Key forces shaping LATAM women hypoactive sexual desire disorder treatment industry/market
3.4.Top player positioning, 2019
3.5.Annual Spending, 2019
3.6.Market dynamics

3.6.1.Drivers

3.6.1.1.Surge in prevalence of lifestyle ailments
3.6.1.2.Rise in use of medicines that induce hypoactive sexual desire disorder
3.6.1.3.Rise in number of surgical procedures leading to sexual dysfunction

3.6.2.Restraint

3.6.2.1.Lack in awareness related to hypoactive sexual desire disorder

3.6.3.Opportunity

3.6.3.1.Presence of strong pipeline products

3.7.Impact Analysis
3.8.COVID-19 Impact Analysis on LATAM women hypoactive sexual desire disorder treatment market
3.9.Cognitive Behavior Therapy

3.9.1.Key market trends, growth factors, and opportunities
3.9.2.Market analysis, by country

CHAPTER 4:LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TYPE

4.1.Overview

4.1.1.Market size and forecast

4.2.Buspirone

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market analysis, by country

4.3.Bupropion

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market analysis, by country

4.4.Bremelanotide

4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market analysis, by country

4.5.Flibanserin

4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market analysis, by country

CHAPTER 5:LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL

5.1.Overview

5.1.1.Market size and forecast

5.2.Hospitals

5.2.1.Market analysis, by country

5.3.Clinics

5.3.1.Market analysis, by country

5.4.Online Retailers

5.4.1.Market analysis, by country

CHAPTER 6:LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY COUNTRY

6.1.Overview

6.1.1.Market size and forecast, by country

6.2.Brazil

6.2.1.Key market trends and growth opportunities
6.2.2.Brazil hypoactive sexual desire disorder (HSDD) treatment market, by treatment type
6.2.3.Brazil hypoactive sexual desire disorder (HSDD) treatment market, by sales channel

6.3.Argentina

6.3.1.Key market trends and growth opportunities
6.3.2.Argentina hypoactive sexual desire disorder (HSDD) treatment market, by treatment type
6.3.3.Argentina hypoactive sexual desire disorder (HSDD) treatment market, by sales channel

6.4.Chile

6.4.1.Key market trends and growth opportunities
6.4.2.Chile hypoactive sexual desire disorder (HSDD) treatment market, by treatment type
6.4.3.Chile hypoactive sexual desire disorder (HSDD) treatment market, by sales channel

6.5.Colombia

6.5.1.Key market trends and growth opportunities
6.5.2.Colombia hypoactive sexual desire disorder (HSDD) treatment market, by treatment type
6.5.3.Colombia hypoactive sexual desire disorder (HSDD) treatment market, by sales channel

6.6.Rest of LATAM

6.6.1.Key market trends and growth opportunities
6.6.2.Rest of LATAM women hypoactive sexual desire disorder (HSDD) treatment market, by treatment type
6.6.3.Rest of LATAM women hypoactive sexual desire disorder (HSDD) treatment market, by sales channel

CHAPTER 7:COMPANY PROFILES

7.1.AUROBINDO PHARMA

7.1.1.Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product portfolio

7.1.5.Business performance.

7.2.BRISTOL-MYERS SQUIBB COMPANY

7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Operating business segments
7.2.4.Product Portfolio
7.2.5.Business performance

7.3.GLAXOSMITHKLINE PLC (GSK)

7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Operating business segments
7.3.4.Product portfolio
7.3.5.Business performance.

7.4.MYLAN N.V.

7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product portfolio
7.4.5.Business performance

7.5.NOVARTIS INTERNATIONAL AG

7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product portfolio
7.5.5.Business performance

7.6.PALATIN TECHNOLOGIES, INC.

7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance.
7.6.6.Key strategic moves and developments

7.7.SPROUT PHARMACEUTICALS, INC.

7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Operating business segments
7.7.4.Product portfolio
7.7.5.Key strategic moves and developments

7.8.SUN PHARMACEUTICAL INDUSTRIES LIMITED

7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.8.5.Business performance

7.9.TEVA PHARMACEUTICAL INDUSTRIES LTD. (ACTAVIS GENERICS)

7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.9.5.Business performance

7.10.ZYDUS CADILA

7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.10.5.Business performance.

LIST OF TABLES

TABLE 01.ANNUAL SPENDING ON WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT, BY COUNTRY, 2019 (US$)
TABLE 02.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR COGNITIVE BEHAVIOR THERAPY, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 03.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR COGNITIVE BEHAVIOR THERAPY, BY COUNTRY, 2019–2027 (NUMBER OF SESSIONS)
TABLE 04.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE,  2019–2027 ($MILLION)
TABLE 05.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TYPE, 2019–2027  (MILLION UNITS)
TABLE 06.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR BUSPIRONE, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 07.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR BUSPIRONE, BY COUNTRY, 2019–2027 (MILLION UNITS)
TABLE 08.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR BUPROPION, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 09.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR BUPROPION, BY COUNTRY, 2019–2027 (MILLION UNITS)
TABLE 10.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR BREMELANOTIDE, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 11.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR BREMELANOTIDE, BY COUNTRY, 2019–2027 (MILLION UNITS)
TABLE 12.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR FLIBANSERIN, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 13.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR FLIBANSERIN, BY COUNTRY, 2019–2027 (MILLION UNITS)
TABLE 14.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 15.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019–2027 (MILLION UNITS)
TABLE 16.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR HOSPITALS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 17.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR HOSPITALS, BY COUNTRY, 2019–2027 (MILLION UNITS)
TABLE 18.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR CLINICS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 19.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR CLINICS, BY COUNTRY,  2019–2027 (MILLION UNITS)
TABLE 20.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR ONLINE RETAILERS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 21.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR ONLINE RETAILERS, BY COUNTRY, 2019–2027 (MILLION UNITS)
TABLE 22.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET REVENUE, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 23.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET REVENUE, BY COUNTRY, 2019–2027 (MILLION UNITS)
TABLE 24.BRAZIL HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019–2027 ($MILLION)
TABLE 25.BRAZIL HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019–2027 (MILLION UNITS)
TABLE 26.BRAZIL HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 27.BRAZIL HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019–2027 (MILLION UNITS)
TABLE 28.ARGENTINA HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019–2027 ($MILLION)
TABLE 29.ARGENTINA HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019–2027 (MILLION UNITS)
TABLE 30.ARGENTINA HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 31.ARGENTINA HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019–2027 (MILLION UNITS)
TABLE 32.CHILE HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019–2027 ($MILLION)
TABLE 33.CHILE HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019–2027 (MILLION UNITS)
TABLE 34.CHILE HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 35.CHILE HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019–2027 (MILLION UNITS)
TABLE 36.COLOMBIA HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019–2027 ($MILLION)
TABLE 37.COLOMBIA HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019–2027 (MILLION UNITS)
TABLE 38.COLOMBIA HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 39.COLOMBIA HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019–2027 (MILLION UNITS)
TABLE 40.REST OF LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019–2027 ($MILLION)
TABLE 41.REST OF LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019–2027 (MILLION UNITS)
TABLE 42.REST OF LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL,  2019–2027 ($MILLION)
TABLE 43.REST OF LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL,  2019–2027 (MILLION UNITS)
TABLE 44.AUROBINDO: COMPANY SNAPSHOT
TABLE 45.AUROBINDO: PRODUCT PORTFOLIO
TABLE 46.BMS: COMPANY SNAPSHOT
TABLE 47.BMS: PRODUCT PORTFOLIO
TABLE 48.GSK: COMPANY SNAPSHOT
TABLE 49.GSK: OPERATING SEGMENTS
TABLE 50.GSK: PRODUCT PORTFOLIO
TABLE 51.MYLAN: COMPANY SNAPSHOT
TABLE 52.MYLAN: OPERATING BUSINESS SEGMENTS
TABLE 53.MYLAN: PRODUCT PORTFOLIO
TABLE 54.NOVARTIS: COMPANY SNAPSHOT
TABLE 55.NOVARTIS: OPERATING SEGMENTS
TABLE 56.NOVARTIS: PRODUCT PORTFOLIO
TABLE 57.PALATIN: COMPANY SNAPSHOT
TABLE 58.PALATIN: PRODUCT PORTFOLIO
TABLE 59.SPROUT: COMPANY SNAPSHOT
TABLE 60.SPROUT: OPERATING SEGMENTS
TABLE 61.SPROUT: PRODUCT PORTFOLIO
TABLE 62.SPROUT: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 63.SUN PHARMA: COMPANY SNAPSHOT
TABLE 64.SUN PHARMA: OPERATING SEGMENTS
TABLE 65.SUN PHARMA: PRODUCT PORTFOLIO
TABLE 66.TEVA: COMPANY SNAPSHOT
TABLE 67.TEVA: OPERATING SEGMENTS
TABLE 68.TEVA: PRODUCT PORTFOLIO
TABLE 69.ZYDUS: COMPANY SNAPSHOT
TABLE 70.ZYDUS: OPERATING SEGMENTS
TABLE 71.ZYDUS: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER TREATMENT MARKET SEGMENTATION:
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.MODERATE BARGAINING POWER OF SUPPLIER
FIGURE 04.LOW BARGAINING POWER OF BUYERS
FIGURE 05.LOW THREAT OF SUBSTITUTES
FIGURE 06.HIGH INTENSITY OF RIVALRY
FIGURE 07.MODERATE THREAT OF NEW ENTRANT
FIGURE 08.TOP PLAYER POSITIONING, 2019
FIGURE 09.IMPACT ANALYSIS, LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER TREATMENT MARKET
FIGURE 10.AUROBINDO: NET SALES, 2018–2020 ($MILLION)
FIGURE 11.AUROBINDO: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 12.BMS: NET SALES, 2017–2019 ($MILLION)
FIGURE 13.BMS: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 14.GSK: NET SALES, 2017–2019 ($MILLION)
FIGURE 15.GSK: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 16.GSK: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 17.MYLAN: NET SALES, 2017–2019 ($MILLION)
FIGURE 18.MYLAN: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 19.NOVARTIS: NET SALES, 2017–2019 ($MILLION)
FIGURE 20.NOVARTIS: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 21.NOVARTIS: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 22.PALATIN: NET SALES, 2018–2020 ($MILLION)
FIGURE 23.SUN PHARMA: NET SALES, 2018–2020 ($MILLION)
FIGURE 24.SUN PHARMA: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 25.SUN PHARMA: REVENUE SHARE, BY GEOGRAPHY, 2020 (%)
FIGURE 26.TEVA: NET SALES, 2017–2019 ($MILLION)
FIGURE 27.TEVA: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 28.TEVA: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 29.ZYDUS: NET SALES, 2018–2020 ($MILLION)
FIGURE 30.ZYDUS: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 31.ZYDUS: REVENUE SHARE, BY REGION, 2020 (%)

 
 

The use of women hypoactive sexual desire disorder (HSDD) treatment products are anticipated to witness a significant growth, owing to rise in use of medicines that induce the state of hypoactive sexual desire disorder, and increase in number of surgical procedures which lead to sexual dysfunction. In addition, increase in prevalence of hypoactive sexual desire disorder has led to surge in demand for new treatment options, which is expected to drive the market growth during the forecast period. 

Presence of pipeline drugs offers lucrative opportunity for the LATAM women hypoactive sexual desire disorder treatment market. Major factors that hinder growth of the market include lack of awareness related to hypoactive sexual desire disorder, which leads to limited diagnosis and treatment. For instance, there is lack of public education on sexual health issues in many countries of Latin America such as Brazil and Guyana.

 
PURCHASE OPTIONS

Start reading instantly ,This title and over 12000 thousand more,available with Avenue Library, T&C*

PURCHASE OPTIONS

Start reading instantly ,This title and over 12000 thousand more,available with Avenue Library, T&C*

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,   
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com

FREQUENTLY ASKED QUESTIONS?
Our Report Looks Like This
 

A. The total market value of LATAM women hypoactive sexual desire disorder treatment market is $966.58 million in 2019.

A. The forecast period for LATAM women hypoactive sexual desire disorder treatment market is 2020 to 2027

A. The market value of LATAM women hypoactive sexual desire disorder treatment market in 2020 is $842.19 million.

A. The base year is 2019 in LATAM women hypoactive sexual desire disorder treatment market

A. Top companies such as, GlaxoSmithKline plc, Bristol Myers Squibb, Mylan N.V., Palatin Technologies, Inc., and Sprout Pharmaceuticals, Inc held a high market position in 2019. These key players held a high market postion owing to the strong geographical foothold in different regions.

A. Bremelanotide segment is the most influencing segment as this medications is FDA approved for use in HSDD in women. Furthermore, the product has lesser side effects related to other options available in the market.

A. The major factor that fuels the growth of the LATAM women hypoactive sexual desire disorder treatment market includes rise in prevalence of lifestyle ailments such as stress, depression which can contribute to development of hypoactive sexual desire disorder in women.

A. Argentina has the highest growth rate in the market with a CAGR of 7.7%. This is due to rise in healthcare expenditure in the region and surge in awareness related to treatment of hypoactive sexual desire disorder.

A. Medical care given to a women suffering from hypoactive sexual desire disorder is termed as hypoactive sexual desrie disorder treatment. Furthermore, the treatment includes use of various drugs such as buspirone, bupropion and others.

A. Hypoactive sexual desire disorder treatments include different kinds of drugs which work through different mechanisms to increase the low sexual desire in women.

Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research
 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
LATAM women Hypoactive Sexual Desire Disorder (HSDD) Treatment Market

  • Online Only
  • $2,735
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $3,039
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $4,649
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $5,105
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $7,119
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $ 699/mo
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Start reading instantly.
    This title and over 12,000+ are available on the Avenue Library. T&C*.

    Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts